{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:18:07Z","timestamp":1785251887602,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pirfenidone is an anti-fibrotic agent shown to slow the progression of idiopathic pulmonary fibrosis (IPF). However, its effectiveness in association with serological autoimmune features in IPF remains unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed the medical records of patients with IPF treated at a tertiary care hospital in South Korea. The autoantibody status was defined as positive if we detected autoantibodies meeting the serological domain criteria for interstitial pneumonia with autoimmune features or anti-neutrophil cytoplasmic antibodies.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 142 patients with IPF treated with pirfenidone for over six months (93 were autoantibody-positive and 49 were autoantibody-negative). The mean age was 69.5\u2009\u00b1\u20097.3\u00a0years, and 77.5% of the patients were male. The adjusted mean changes over one year were\u2009\u2212\u200934.4 and\u2009\u2212\u2009112.2\u00a0mL (<jats:italic>p<\/jats:italic>\u2009=\u20090.168) in forced vital capacity (FVC), and\u2009\u2212\u20090.53 and\u2009\u2212\u20090.72\u00a0mL\/mmHg\/min (<jats:italic>p<\/jats:italic>\u2009=\u20090.356) in the lungs diffusion capacity for carbon monoxide (DL<jats:sub>CO<\/jats:sub>) in the autoantibody-negative and autoantibody-positive groups, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Reductions in FVC and DL<jats:sub>CO<\/jats:sub> were similar in autoantibody-positive and autoantibody-negative patients with IPF treated with pirfenidone. Pirfenidone is effective in attenuating the progression of IPF, irrespective of the autoantibody status.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-021-01516-4","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T14:50:54Z","timestamp":1620053454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Myung Jin","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Ye","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Sam","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Yee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"issue":"5","key":"1516_CR1","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"1516_CR2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","volume":"175","author":"JH Park","year":"2007","unstructured":"Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175(7):705\u201311.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1516_CR3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1378\/chest.12-0741","volume":"143","author":"R Vij","year":"2013","unstructured":"Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143(3):814\u201324.","journal-title":"Chest"},{"key":"1516_CR4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.rmed.2016.05.030","volume":"117","author":"M Kono","year":"2016","unstructured":"Kono M, Nakamura Y, Yoshimura K, Enomoto Y, Oyama Y, Hozumi H, et al. Nonspecific interstitial pneumonia preceding diagnosis of collagen vascular disease. Respir Med. 2016;117:40\u20137.","journal-title":"Respir Med"},{"issue":"8","key":"1516_CR5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11926-013-0349-8","volume":"15","author":"B Hervier","year":"2013","unstructured":"Hervier B, Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep. 2013;15(8):349.","journal-title":"Curr Rheumatol Rep"},{"key":"1516_CR6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/0002-9343(91)90190-9","volume":"91","author":"RH Shmerling","year":"1991","unstructured":"Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med. 1991;91:528\u201334.","journal-title":"Am J Med"},{"issue":"6","key":"1516_CR7","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1183\/13993003.01565-2015","volume":"47","author":"JM Oldham","year":"2016","unstructured":"Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016;47(6):1767.","journal-title":"Eur Respir J"},{"issue":"4","key":"1516_CR8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976\u201387.","journal-title":"Eur Respir J"},{"key":"1516_CR9","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1378\/chest.10-2662","volume":"140","author":"R Vij","year":"2011","unstructured":"Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011;140:1292\u20139.","journal-title":"Chest"},{"issue":"2","key":"1516_CR10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rmed.2012.10.018","volume":"107","author":"JS Lee","year":"2013","unstructured":"Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, et al. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med. 2013;107(2):249\u201355.","journal-title":"Respir Med"},{"issue":"4","key":"1516_CR11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.mayocp.2013.11.018","volume":"89","author":"T Moua","year":"2014","unstructured":"Moua T, Maldonado F, Decker PA, Daniels CE, Ryu JH. Frequency and implication of autoimmune serologies in idiopathic pulmonary fibrosis. Mayo Clin Proc. 2014;89(4):319\u201326.","journal-title":"Mayo Clin Proc"},{"key":"1516_CR12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.rmed.2019.07.001","volume":"155","author":"B Ghang","year":"2019","unstructured":"Ghang B, Lee J, Kwon CO, Ahn SM, Oh JS, Hong S, et al. Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis. Respir Med. 2019;155:43\u20138.","journal-title":"Respir Med"},{"key":"1516_CR13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.rmed.2019.05.019","volume":"153","author":"GC Goobie","year":"2019","unstructured":"Goobie GC, Ford-Sahibzada CA, Fritzler MJ, Johannson KA, Fell CD. Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis. Respir Med. 2019;153:85\u201390.","journal-title":"Respir Med"},{"issue":"6","key":"1516_CR14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1516_CR15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/art.11113","volume":"49","author":"JD Reveille","year":"2003","unstructured":"Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49(3):399\u2013412.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1516_CR16","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/art.34380","volume":"64","author":"M Satoh","year":"2012","unstructured":"Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64(7):2319\u201327.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1516_CR17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5114\/reum.2018.77976","volume":"56","author":"B Grygiel-G\u00f3rniak","year":"2018","unstructured":"Grygiel-G\u00f3rniak B, Rogacka N, Puszczewicz M. Antinuclear antibodies in healthy people and non-rheumatic diseases - diagnostic and clinical implications. Reumatologia. 2018;56(4):243\u20138.","journal-title":"Reumatologia"},{"key":"1516_CR18","doi-asserted-by":"crossref","unstructured":"Parra ER, Kairalla RA, Ribeiro de Carvalho CR, Eher E, Capelozzi VL. Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. Respiration. 2007;74(2):159\u201369.","DOI":"10.1159\/000097133"},{"issue":"5","key":"1516_CR19","doi-asserted-by":"crossref","first-page":"e0154516-e","DOI":"10.1371\/journal.pone.0154516","volume":"11","author":"E Balestro","year":"2016","unstructured":"Balestro E, Calabrese F, Turato G, Lunardi F, Bazzan E, Marulli G, et al. Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis. PloS one. 2016;11(5):e0154516-e.","journal-title":"PloS one."},{"issue":"4","key":"1516_CR20","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.4049\/jimmunol.179.4.2592","volume":"179","author":"CA Feghali-Bostwick","year":"2007","unstructured":"Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol. 2007;179(4):2592\u20139.","journal-title":"J Immunol"},{"issue":"6","key":"1516_CR21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1164\/rccm.201010-1727ED","volume":"183","author":"CA Feghali-Bostwick","year":"2011","unstructured":"Feghali-Bostwick CA, Wilkes DS. Autoimmunity in idiopathic pulmonary fibrosis: are circulating autoantibodies pathogenic or epiphenomena? Am J Respir Crit Care Med. 2011;183(6):692\u20133.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4 Pt 1","key":"1516_CR22","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.159.4.9805017","volume":"159","author":"G Raghu","year":"1999","unstructured":"Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1061\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1516_CR23","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/art.10561","volume":"47","author":"DH Solomon","year":"2002","unstructured":"Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47(4):434\u201344.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1516_CR24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5124\/jkma.2020.63.1.47","volume":"63","author":"C Won-Il","year":"2020","unstructured":"Won-Il C. Pharmacological treatment of pulmonary fibrosis. J Korean Med Assoc (Korean). 2020;63(1):47\u201355.","journal-title":"J Korean Med Assoc (Korean)"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01516-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-021-01516-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01516-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T14:51:51Z","timestamp":1620053511000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-021-01516-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1186\/s12890-021-01516-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board (IRB) and Ethics Committee of Severance Hospital approved this study (number: 4-2018-0435). The need for written informed consent was waived by the IRB due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}